AbCellera Biologics (ABCL) has drawn investor attention after appointing Victor Sandor, M.D.C.M, as an independent director. He brings drug development and regulatory approval experience from roles at Array BioPharma, Incyte, Biogen and AstraZeneca.

The appointment of Victor Sandor comes as AbCellera’s share price has climbed 47.61% over the past 90 days and 52.77% year to date. The 1-year total shareholder return of 65.82% contrasts with a 3-year total shareholder return that has declined 30.87%, suggesting that recent momentum is rebuilding after earlier weakness.

If this kind of biotech story has your attention, it could be a good moment to see what else is setting up in healthcare AI by checking out 40 healthcare AI stocks

With AbCellera’s stock up sharply over the past year, but longer term returns still under pressure and the business reporting US$79.21 million in revenue against a net loss of US$143.96 million, is this a reset entry point or is the market already pricing in future growth?

Most Popular Narrative: 49.8% Undervalued

Analysts following AbCellera see fair value at $10.43 versus a last close of $5.24, and that gap underpins the most widely followed narrative on the stock.

The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long-term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

Want to see what is baked into that near doubling between price and fair value? The narrative focuses on revenue mix, margin uplift and the use of high future earnings multiples in valuation.

Result: Fair Value of $10.43 (UNDERVALUED)

However, investors still need to watch execution risk on the menopause program, as well as the reliance on very large future P/E multiples to justify the analyst narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Price To Sales Sends A Different Signal

While the analyst narrative points to a fair value of $10.43, the current P/S of 20.2x is far above the US Life Sciences industry at 3.7x, the peer average at 8.6x, and an estimated fair ratio of just 0.3x, which points to meaningful valuation risk if sentiment cools.

That kind of gap can close in more than one way, so the key question is whether you think AbCellera grows into this pricing or whether the multiple does most of the moving.

Next Steps

With optimism and concern both on the table, this is the moment to look through the numbers yourself and decide where you stand. To see the key issues investors are focused on, including 1 key reward and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing smarter opportunities elsewhere, so widen your watchlist now and let the numbers work for you.

• Target reliable cash generators by scanning companies in the solid balance sheet and fundamentals stocks screener (48 results).
• Spot potential mispricings early by reviewing the screener containing 20 high quality undiscovered gems.
• Prioritize stability and sleep-better-at-night holdings using the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.